¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"heat shock response"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • recruiting response
    µ¿¿ø¹ÝÀÀ
  • response
    ¹ÝÀÀ
  • response bias
    ¹ÝÀÀÄ¡¿ìħ
  • response curve
    ¹ÝÀÀ°î¼±
  • response decline
    ¹ÝÀÀ°¨¼Ò
  • response frequency
    ¹ÝÀÀÁ֯ļö
  • response modulation
    ¹ÝÀÀÁ¶Á¤
  • response prevention
    ¹ÝÀÀ¿¹¹æ
  • response rate
    ¹ÝÀÀ·ü
  • reticulocyte response
    ±×¹°ÀûÇ÷±¸¹ÝÀÀ, ¸Á»óÀûÇ÷±¸¹ÝÀÀ
  • startle response
    ³î¶÷¹ÝÀÀ
  • startle response audiometry
    ³î¶÷¹ÝÀÀû·Â°Ë»ç
  • stereotyped response
    ÀÚµ¿¹Ýº¹¹ÝÀÀ, »óµ¿¹ÝÀÀ
  • stimulus response assessment
    ÀڱعÝÀÀÆò°¡
  • subthreshold response
    ¹®ÅιعÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • heat labile antibody
    ¿­¹Î°¨Ç×ü
  • heat resisting alloy
    ³»¿­ÇÕ±Ý
  • body heat
    ü¿­
  • incomplete heat beat
    ºÒ¿ÏÀü½ÉÀå¹Úµ¿
  • intraventricular heat beat
    ½É½Ç³»½É¹Úµ¿
  • combustion heat
    ¿¬¼Ò¿­
  • conductive heat
    Àüµµ¿­
  • convection heat
    ´ë·ù¿­
  • conversion heat
    Àüȯ¿­
  • heat capacity
    ¿­¿ë·®
  • heat cataract
    ¿­¹é³»Àå
  • heat collapse
    ¿­ÇãÅ»
  • heat conduction
    ¿­Àüµµ
  • heat cramp
    ¿­°æ·Ã
  • heat-regulating center
    ü¿ÂÁ¶ÀýÁßÃß
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • heat pyrexia
    ¿­»çº´(æðÞÒÜ»).
  • heat radiation
    ¿­¹æ»ç(ËçËÑË×).
  • heat radiation
    ¿­¹æ»ç(æðÛ¯ÞÒ).
  • heat rash = miliaria rubra
    È«»öÇÑÁø(ûõßäùÒòÖ)
  • heat regulation
    ü¿Â(¿­)Á¶Àý(ô÷è®æððàï½).
  • heat regulatory center
    ü¿ÂÁ¶ÀýÁßÃß(¡­ñéõÒ).
  • heat resistance
    ³»¿­¼º(Ò±æðàõ).
  • heat resistance
    ³»¿­¼º(ËÀËçËÛ).
  • heat resisting alloy
    ³»¿­ÇÕ±Ý(Ò±æðùêÐÝ).
  • heat resisting alloy
    ³»¿­ÇÕ±Ý(ËÀËç̰˻).
  • heat resisting steel
    ³»¿­°­(Ò±æð˼).
  • heat resisting steel
    ³»¿­°­(ËÀËç˧).
  • heat retention
    ¿ï¿­(ê¦æð), ¿­Á¤Ã¼(æðïÒô÷).
  • heat retention
    ¿ï¿­(ËôËç), ¿­Á¤Ã¼(ËçËøÌ§).
  • heat reversible
    ¿­°¡¿ª¼º(æðʦæ½àõ)ÀÇ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • attention response
    ÁÖÀÇ·Â ¹ÝÀÀ
  • audiometry, brainstem evoked response =BERA
    ³ú°£À¯¹ß¹ÝÀÀ û·Â°Ë»ç
  • audiometry, evoked response
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • audiometry, galvanic skin response =GSR-a.
    ÇǺÎÀü±â¹ÝÀÀ û·Â°Ë»ç
  • audiometry, startle response
    °æ¾Ç¹ÝÀÀû·Â°Ë»ç
  • autoimmune response
    ÀÚ°¡¸é¿ª(í»Ê«Øóæµ) ¹ÝÀÀ(Úãëë)
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • avoidance reaction =a. response
    ȸÇǹÝÀÀ(üÞù­Úãëë)
  • biologic response modifier, BRM
    »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • biologic response modifiers
    »ý¹°ÇÐÀû ¹ÝÀÀÁ¶ÀýÁ¦
  • biological response modifier (BRM)
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶Àý¹°Áú (BRM)
  • brainstem evoked response =BER
    ³ú°£À¯¹ß¹ÝÀÀ
  • brainstem evoked response audiometry =BERA
    ³ú°£À¯¹ß¹ÝÀÀ û·Â°Ë»ç
  • bulbocavernous evoked-response test
    ±¸Çظéü À¯¹ß¹ÝÀÀ°Ë»ç
  • cellular response
    ¼¼Æ÷¼º¹ÝÀÀ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
HS Haber syndrome; half strength; hamstring; hand surgery; Hartmann solution; head sling; healthy subje...
HSAP heat-stable alkaline phosphatase
HSI heat stress index; human seminal plasma inhibitor
HU heat unit; hemagglutinating unit; hemolytic unit; Hounsfield unit; human urine, human urinary; hydro...
JH heat transfer factor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
HST heat stress test
HME Heat and Moisture Exchangers
HP Heat production
HS Heat stress
hsp Heat stress proteins
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
late-phase response Recurrence of symptoms after an appreciable interval following challenge with an antigen; preceded by an initial early-phase response.
(05 Mar 2000)
lh response to gnrh This test measures the level of luteinising hormone in the blood after an injection of gonadotrophin releasing hormone (GNRH), normally produced in the hypothalamus. This will test the ability of the pituitary gland to respond by measuring one of the pituitary glands byproducts, luteinising hormone. This test is used to differentiate hypogonadism (ovary or testes) into primary hypogonadism (problem is with the ovary or testes) or secondary hypogonadism (problem is with the pituitary gland or the hypothalamus).
(27 Sep 1997)
lymphoproliferative response <haematology, immunology> A specific immune response that entails rapid T-cell replication. Standard antigens, such as tetanus toxoid, that elicit this response are used in lab tests of immune competence.
(13 Nov 1997)
anaesthetic shock Shock produced by the administration of anaesthetic drug(s), usually in relative overdosage.
(05 Mar 2000)
anaphylactic shock <immunology> A serious, often life-threatening allergic reaction that is characterised by low blood pressure, shock (poor tissue perfusion) and difficulty breathing.
(27 Sep 1997)
anaphylactoid shock A reaction that is similar to anaphylactic shock, but which does not require the incubation period characteristic of induced sensitivity (anaphylaxis); it is unrelated to antigen-antibody reactions.
Synonym: anaphylactoid crisis, pseudoanaphylactic shock.
(05 Mar 2000)
break shock The shock produced by breaking a constant current passing through the body.
(05 Mar 2000)
cardiac shock A form of shock (inadequate delivery of oxygen to the tissues) that occurs secondary to the weakened pumping function of the heart. This condition may be precipitated by myocardial infarction or cardiomyopathy.
Treatment includes fluid restriction, diuretics, vasopressors (dopamine) to support the blood pressure and the use of intravenous medications (dobutamine) which stimulate the heart to contract more forcefully.
(27 Sep 1997)
cardiogenic shock A form of shock (inadequate delivery of oxygen to the tissues) that occurs secondary to the weakened pumping function of the heart. This condition may be precipitated by myocardial infarction or cardiomyopathy.
Treatment includes fluid restriction, diuretics, vasopressors (dopamine) to support the blood pressure and the use of intravenous medications (dobutamine) which stimulate the heart to contract more forcefully.
(27 Sep 1997)
cardiopulmonary obstructive shock <cardiology> This term describes a number of conditions that involve a severe disturbance of the cardiopulmonary circuit resulting in shock (inadequate delivery of oxygen to the tissues).
Examples include: pulmonary embolism, pericardial tamponade, pneumothorax and constrictive pericarditis.
(27 Sep 1997)
vasogenic shock Shock resulting from depressed activity of the higher vasomotor centres in the brain stem and the medulla, producing vasodilation without loss of fluid so that the container is disproportionately large. In oligaemic shock, blood volume is reduced; in both, return of venous blood is inadequate.
(05 Mar 2000)
reversible shock Shock that will respond to treatment and from which recovery is possible.
(05 Mar 2000)
chronic shock The state of peripheral circulatory insufficiency developing in elderly patients with a debilitating disease, e.g., carcinoma; a subnormal blood volume makes the patient susceptible to haemorrhagic shock as a result of even a moderate blood loss such as may occur during an operation.
(05 Mar 2000)
wet shock A severe condition that occurs when the level of blood glucose (sugar) drops quickly. The signs are shaking, sweating, dizziness, double vision, convulsions, and collapse. Insulin shock may occur when an insulin reaction is not treated quickly enough.
See: hypoglycaemia.
(09 Oct 1997)
cultural shock A form of stress associated with the beginning of an individual's assimilation into a new culture vastly different from that in which he or she was raised.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á